Company Overview - EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal diseases [3][4] - The company's lead product candidate, DURAVYU™, is an investigational sustained delivery treatment combining vorolanib, a selective tyrosine kinase inhibitor, with next-generation bioerodible Durasert E™ technology [3][5] - EyePoint has a history of four approved drugs over three decades and has treated tens of thousands of eyes with its innovations [4] Product Development - DURAVYU™ is currently undergoing Phase 3 pivotal trials for wet age-related macular degeneration, with topline data expected in mid-2026 [3] - The first patient dosing in the pivotal Phase 3 clinical trials for diabetic macular edema is anticipated in the first quarter of 2026 [3] Corporate Events - George O. Elston, Executive Vice President and Chief Financial Officer of EyePoint, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 [1] - A webcast and archived replay of the fireside chat will be available on the company's website [2]